Jaguar Health Q3 2026 product revenue falls 81.9%
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jaguar Health, Inc. (JAGX) reported third-quarter 2026 results, including total revenue of $2.343 million, down 24.0% from $3.083 million in Q3 2025. Product revenue was $551,000 versus $3.041 million, while license and grant revenue was $1.792 million versus $42,000.
Loss from operations was $6.023 million, compared with $7.238 million in Q3 2025; net loss was $5.830 million versus $9.648 million. Non-GAAP recurring EBITDA was a loss of $5.032 million, compared with $9.025 million, and non-GAAP EBITDA was a loss of $5.590 million versus $9.025 million. Jaguar says these non-GAAP measures are not substitutes for, or superior to, GAAP measures and should not be viewed in isolation.
Jaguar said it reduced its outstanding debt balance by $10.1 million in Q3 2026. Its rare-disease intestinal failure program for crofelemer powder for oral solution, targeting microvillus inclusion disease and short bowel syndrome, is expected to continue providing clinical milestones, including a planned NDA filing for MVID in mid-2027. Mytesi is indicated for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointOutstanding debt declined by $10.1 million in Q3 2026. 1.8× market cap
- Moderate pointNet loss narrowed 39.6% to $5.830 million in Q3 2026.
Negative
- Moderate pointTotal revenue fell 24.0% to $2.343 million in Q3 2026.
- Minor pointProduct revenue declined 81.9% to $551,000 in Q3 2026.
Filing Explained
The 8-K reports Jaguar’s third-quarter 2026 results; at
Sources and calculations
- Jaguar Health Form 8-K and Exhibit 99.1 (2026-11-16)
- Jaguar Health Q3 2026 fundamentals (2026Q3)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $5,528,000 / ($4,929,000 / 92) = 103.2 days
8-K Event Classification
Key Figures
Key Terms
Non-GAAP Recurring EBITDA financial
New Drug Application (NDA) regulatory
microvillus inclusion disease (MVID) medical
intestinal failure medical
short bowel syndrome medical
botanical guidance regulatory
Earnings Snapshot
Jaguar expects a planned NDA filing for crofelemer for MVID in mid-2027.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did JAGX revenue change in Q3 2026?
When does JAGX expect to file an NDA for crofelemer for MVID?
AI-generated analysis. How Rhea-AI works. Not financial advice.